CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Transseptal puncture versus patent foramen ovale or atrial septal defect access for left atrial appendage closure Thirty-Day Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study Results Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure Results From the CABANA Trial MITRA-FR vs. COAPT: Lessons from two trials with diametrically opposed results Percutaneous Left Atrial Appendage Occlusion for Patients in Atrial Fibrillation Suboptimal for Warfarin Therapy: 5-year Results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study Current Status and Future Prospects of Transcatheter Mitral Valve Replacement: JACC State-of-the-Art Review The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC Systematic Review and Network Meta‐Analysis Comparing Bifurcation Techniques for Percutaneous Coronary Intervention 2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes

Original Research2017 Dec 5. [Epub ahead of print]

JOURNAL:Catheter Cardiovasc Interv. Article Link

Rotational atherectomy and new-generation drug-eluting stent implantation

Hachinohe D, Kashima Y, Kanno D et al. Keywords: newer-generation drug-eluting stents; percutaneous coronary intervention; rotational atherectomy

ABSTRACT


OBJECTIVES - The aim of this study was to evaluate the clinical outcomes of rotational atherectomy (RA) followed by new-generation drug-eluting stent (DES) implantation in patients with an extensive amount of calcified and fibrotic plaque.


BACKGROUND - RA followed by new-generation DES implantation for complex lesions has not been thoroughly evaluated.


METHODS - A total of 744 consecutive patients (770 lesions) treated with new-generation DES implantation following RA for de novo lesions between January 2013 and November 2015 were retrospectively identified using our institutional database. Clinical outcomes at 12 months were evaluated and the independent predictors of all-cause death and target vessel failure (TVF) were assessed using Cox regression models.


RESULTS - Target lesion revascularization occurred in 22 lesions (2.9%) and TVF occurred in 51 lesions (6.6%). In a multivariate analysis, hemodialysis, non-ST-segment elevation acute coronary syndrome, low ejection fraction, and HbA1c ≧ 7% were associated with 12-month mortality. Hemodialysis and right coronary artery were identified as independent predictors of TVF (hazard ratio (HR) 4.107, 95% confidence interval (CI) 2.194-7.685, P < .001; HR 2.491, 95% CI 1.023-6.062, P = .044, respectively).


CONCLUSIONS - A good debulking with RA followed by new-generation DES implantation is recommended for patients with an excessive amount of calcified and fibrotic plaque, as this will likely improve the clinical outcomes.


© 2017 Wiley Periodicals, Inc.